证券代码：300078 证券简称：思创医惠 公告编号：2025-120 思创医惠科技股份有限公司 关于 2026 年度日常关联交易预计的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、日常关联交易基本情况 （一）日常关联交易概述 思创医惠科技股份有限公司（以下简称"公司"）及控股子公司根据《中华 人民共和国公司法》《深圳证券交易所创业板股票上市规则》等相关法律法规、 规范性文件及《公司章程》相关规定，结合以前年度公司及控股子公司实际发生 的日常关联交易情况及未来经营发展需要，预计 2026 年度与关联方浙江码尚科 技股份有限公司（以下简称"码尚科技"）、苍南县山海实业集团有限公司（以 下简称"山海实业"）、医惠科技有限公司（以下简称"医惠科技"）发生日常 关联交易。2026 年度公司及控股子公司拟向码尚科技出售产品、商品的交易金 额预计不超过 1,500.00 万元、拟向码尚科技租赁厂房等交易金额预计不超过 500.00 万元、拟向山海实业租赁办公场所等交易金额预计不超过 2,500.00 万元、 拟向医惠科技租赁办公场所等交易金额预计不超过 500 ...

1、股东会届次：2025 年第七次临时股东会 2、股东会的召集人：董事会 证券代码：300078 证券简称：思创医惠 公告编号：2025-123 思创医惠科技股份有限公司 关于召开 2025 年第七次临时股东会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、召开会议的基本情况 3、本次会议的召集、召开符合《中华人民共和国公司法》《深圳证券交 易所创业板股票上市规则》《深圳证券交易所上市公司自律监管指引第 2 号— 创业板上市公司规范运作》等法律、行政法规、部门规章、规范性文件及《公 司章程》的有关规定。 4、会议时间： （1）现场会议时间：2025 年 12 月 29 日（星期一）15:00 （2）网络投票时间：通过深圳证券交易所系统进行网络投票的具体时间 为 2025 年 12 月 29 日 9:15-9:25，9:30-11:30，13:00-15:00；通过深圳证券 交易所互联网投票系统投票的具体时间为 2025 年 12 月 29 日 9:15 至 15:00 的 任意时间。 5、会议的召开方式：现场表决与网络投票相结合 6、会议的股权登记 ...

证券代码：300078 证券简称：思创医惠 公告编号：2025-119 思创医惠科技股份有限公司 第六届董事会第十五次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 思创医惠科技股份有限公司（以下简称"公司"）第六届董事会第十五次会 议于 2025 年 12 月 12 日在公司会议室以通讯表决的方式召开。会议通知于 2025 年 12 月 11 日通过电子邮件、电话方式送达各位董事，经全体董事一致同意，本 次会议豁免通知期限要求。本次会议应出席董事 8 人，实际出席董事 8 人。会议 由董事长魏乃绪先生召集并主持，公司高级管理人员列席了会议。本次会议的召 集、召开和表决程序符合《中华人民共和国公司法》等法律法规和《公司章程》 的规定。 二、董事会会议审议情况 1、审议通过了《关于 2026 年度日常关联交易预计的议案》 经与会董事审议，公司 2026 年度预计发生的日常关联交易事项，是为了满 足公司及控股子公司生产经营和业务发展需要，关联交易行为属于日常经营相关 的事项，符合公司及控股子公司实际经营需要，交易价格以市场公允 ...

以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。 从资金流向上来看，当日IT服务板块主力资金净流出29.88亿元，游资资金净流入2.0亿元，散户资金净 流入27.88亿元。IT服务板块个股资金流向见下表： 证券之星消息，12月11日IT服务板块较上一交易日下跌1.98%，思创医惠领跌。当日上证指数报收于 3873.32，下跌0.7%。深证成指报收于13147.39，下跌1.27%。IT服务板块个股涨跌见下表： ...

Group 1 - Guizhou BaiLing's actual controller Jiang Wei has been investigated by the China Securities Regulatory Commission (CSRC) for insider trading and information disclosure violations [1] - The investigation highlights the regulatory focus on key individuals and may increase operational uncertainty for Guizhou BaiLing, which has faced performance pressures in recent years [1] - The CSRC's actions reflect ongoing efforts to enhance the rule of law in the capital market [1] Group 2 - Jianyou Co., Ltd. has received ANDA approval from the FDA for its Propofol emulsion injection, marking a significant step in the company's internationalization of its formulations [2] - The product is expected to have a broad market potential in the U.S. as a commonly used sedative for surgeries, potentially driving revenue growth for the company [2] Group 3 - Shenzhen Xinlitai has been granted clinical trial approval for its innovative small molecule drug SAL0140, aimed at treating chronic kidney disease (CKD) [3] - SAL0140 is a proprietary aldosterone synthase inhibitor with potential applications in multiple significant chronic disease areas, indicating substantial market potential [3] - Successful development could open new growth avenues for Shenzhen Xinlitai [3] Group 4 - Junshi Biosciences reported a decrease in the shareholding percentage of Greenland Financial Investment Group and its affiliates from 5.0051% to 4.7129% due to share lending [4] - This change is a technical operation rather than an active reduction in holdings, but it brings the shareholding below the 5% disclosure threshold, warranting market attention on future actions [4] Group 5 - Sichuan Sichuang Medical Technology Co., Ltd. announced the resignation of Chairman Xu Yiran to facilitate governance structure optimization, while he will remain a board member [5] - The appointment of Wei Naixu as the new chairman indicates a strategic move to clarify responsibilities and strengthen governance rather than a response to a crisis [5]

Group 1 - Guizhou BaiLing's actual controller Jiang Wei has been investigated by the China Securities Regulatory Commission (CSRC) for insider trading and information disclosure violations, indicating a focus on regulatory enforcement against key individuals [1] - The investigation may exacerbate operational uncertainties for Guizhou BaiLing, which has faced performance pressures in recent years, raising concerns about corporate governance and information disclosure risks [1] Group 2 - Jianyou Co., Ltd. has received ANDA approval from the FDA for its propofol emulsion injection, marking a significant step in the company's internationalization of its formulations [2] - The product, commonly used for sedation during surgeries, has substantial market potential in the U.S., which is expected to contribute to revenue growth for Jianyou [2] Group 3 - Shenzhen Xinlitai Pharmaceutical Co., Ltd. has been granted clinical trial approval for its innovative small molecule drug SAL0140, aimed at treating chronic kidney disease (CKD) [3] - SAL0140, an aldosterone synthase inhibitor, targets multiple significant chronic disease areas, including uncontrolled hypertension and CKD, presenting considerable market potential for the company [3] Group 4 - Junshi Biosciences reported a decrease in the shareholding percentage of Greenland Financial Investment Group and its affiliates from 5.0051% to 4.7129% due to share lending, falling below the 5% disclosure threshold [4] - This change is primarily a technical operation rather than an active reduction in holdings, but the market will need to monitor the future actions of these shareholders [4] Group 5 - Sichuang Medical Technology has elected Wei Naixu as the new chairman following the resignation of Xu Yiran, who stepped down to facilitate governance structure optimization [5] - Xu Yiran will remain on the board, indicating that the adjustment aims to clarify responsibilities and strengthen governance rather than signaling a crisis [5]

Core Viewpoint - The company, Sichuang Medical Technology Co., Ltd., has undergone significant leadership changes, with the resignation of Chairman Xu Yiran and the appointment of Wei Naixu as the new chairman and legal representative, indicating a restructuring effort within the company's governance [1][2]. Leadership Changes - Xu Yiran resigned from his positions as Chairman, Strategic Decision Committee Chair, and Audit Committee member to facilitate governance optimization, while remaining a board member [1]. - Wei Naixu was elected as the new Chairman and legal representative of the company, with his term starting from the approval date of the board meeting [1]. - Wu Weibin was appointed as the new Deputy General Manager, with his term also starting from the same board meeting [1]. Shareholding and Control - Wei Naixu indirectly holds 20,732,440 shares (1.85% of total shares) through Cangnan Xinchuan and has control over 63,890,185 shares (5.72%) via Cangnan Xincheng, making him the actual controller of the company with a total of 83,471,940 shares (7.47%) after a pending share transfer [2]. - After the share transfer is completed, Wei Naixu will control a total of 147,362,125 shares (13.18% of total shares) [2]. Company Background - Sichuang Medical Technology Co., Ltd. was established in 2003 and listed on the Shenzhen Stock Exchange in April 2010, recognized as a leading provider of smart medical and IoT application solutions [5]. Financial Performance - The company has faced significant financial challenges, reporting continuous net profit losses over the past five years, with cumulative losses exceeding 3 billion yuan [6]. - In the latest financial report, the company achieved a revenue of 603.8 million yuan in the first three quarters, a year-on-year increase of 6.95%, but still reported a net loss of 4.762 million yuan [6].

格隆汇12月3日丨思创医惠（维权）(300078.SZ)公布，董事会于近日收到董事长许益冉先生的书面辞职 报告，许益冉先生为配合公司治理结构优化调整申请辞去第六届董事会董事长、战略决策委员会主任委 员（召集人）以及审计委员会成员职务，并不再担任公司法定代表人，辞职后许益冉先生仍继续担任公 司第六届董事会董事。上述职务原定任期为2024年12月6日至2027年12月5日。 鉴于公司原董事长已辞去董事长职务，并不再担任公司法定代表人，为保证董事会规范运作，公司于 2025年12月3日召开第六届董事会第十四次会议，审议通过了《关于选举第六届董事会董事长、代表公 司执行公司事务的董事的议案》，董事会全体董事一致同意选举魏乃绪先生为公司第六届董事会董事 长、代表公司执行公司事务的董事，任期自第六届董事会第十四次会议审议通过之日起至第六届董事会 任期届满之日止。 ...

北京商报讯（记者 丁宁）12月3日晚间，思创医惠（300078）发布公告称，公司董事会于近日收到董事 长许益冉的书面辞职报告，许益冉为配合公司治理结构优化调整申请辞去第六届董事会董事长、战略决 策委员会主任委员（召集人）以及审计委员会成员职务，并不再担任公司法定代表人，辞职后许益冉仍 继续担任公司第六届董事会董事。 资料显示，魏乃绪1981年出生，现任浙江码尚科技股份有限公司董事长。2024年12月至今，任公司董 事、总经理。 为进一步完善公司治理结构，保障公司各专门委员会能够顺利高效开展工作，充分发挥各位委员的专业 特长，董事会结合公司实际情况对第六届董事会专门委员会部分成员进行调整，公司于12月3日召开第 六届董事会第十四次会议，审议通过了《关于调整第六届董事会专门委员会成员的议案》，选举魏乃绪 为第六届董事会战略决策委员会主任委员（召集人），选举何毅琦为第六届董事会审计委员会成员，将 第六届董事会薪酬与考核委员会委员叶肖剑调整为何毅琦。 ...

证券代码：300078 证券简称：思创医惠 公告编号：2025-118 思创医惠科技股份有限公司 关于董事长辞职及补选董事长、变更法定代表人、调整专门 委员会成员暨聘任副总经理的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 事务的董事担任"，因此代表公司执行公司事务的董事魏乃绪先生将担任公司法 定代表人。公司管理层将尽快按照法定程序完成法定代表人变更的相关工商变更 登记事宜。 三、关于调整专门委员会成员的情况 一、关于董事长辞职的情况 思创医惠科技股份有限公司（以下简称"公司"）董事会于近日收到董事长 许益冉先生的书面辞职报告，许益冉先生为配合公司治理结构优化调整申请辞去 第六届董事会董事长、战略决策委员会主任委员（召集人）以及审计委员会成员 职务，并不再担任公司法定代表人，辞职后许益冉先生仍继续担任公司第六届董 事会董事。上述职务原定任期为 2024 年 12 月 6 日至 2027 年 12 月 5 日。 根据《中华人民共和国公司法》（以下简称"《公司法》"）及《公司章程》 等有关规定，许益冉先生的辞职报告自送达董事会之日起生效。许益冉先生作为 公 ...